AR086673A1 - RESPUESTAS MEJORADAS MEDIADAS POR LES-DC DE CELULAS B QUE SECRETAN IgG E IgA - Google Patents
RESPUESTAS MEJORADAS MEDIADAS POR LES-DC DE CELULAS B QUE SECRETAN IgG E IgAInfo
- Publication number
- AR086673A1 AR086673A1 ARP120101977A ARP120101977A AR086673A1 AR 086673 A1 AR086673 A1 AR 086673A1 AR P120101977 A ARP120101977 A AR P120101977A AR P120101977 A ARP120101977 A AR P120101977A AR 086673 A1 AR086673 A1 AR 086673A1
- Authority
- AR
- Argentina
- Prior art keywords
- expression
- cells
- level
- sindecan
- lupus erythematosus
- Prior art date
Links
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 7
- 238000003745 diagnosis Methods 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000008177 pharmaceutical agent Substances 0.000 abstract 2
- 239000000523 sample Substances 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000013068 control sample Substances 0.000 abstract 1
- 230000004043 responsiveness Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/104—Lupus erythematosus [SLE]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Rehabilitation Therapy (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Método para tratar un paciente en riesgo o con un diagnóstico de lupus eritematoso sistémico (LES) determinando la expresión total de sindecano-1 en una o más células de un pacientes que se sospecha que está afectado por LES y predecir la eficacia de un agente farmacéutico para su tratamiento. Una reducción en la expresión total de sindecano-1 en las células del paciente, en comparación con la expresión de sindecano-1 en células normales, indica una predisposición a la responsividad a una terapia con un agente anti-neoplásico, y la terapia comprende administrar una cantidad eficaz del agente farmacéutico al paciente.Reivindicación 1: Un método para diagnosticar el lupus eritematoso sistémico (SLE), que comprende los siguientes pasos: determinar el nivel de expresión de sindecan-1 en una muestra que ha sido aislada con antelación; comparar el nivel de expresión de sindecan-1 en la muestra con el nivel de expresión normal en una muestra de control, obtenida de un tejido normal conocido; y correlacionar el nivel de expresión de sindecan-1 con un diagnóstico de lupus eritematoso sistémico, donde un nivel de expresión incrementado de sindecan-1 es indicativo de un diagnóstico de lupus eritematoso sistémico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161493755P | 2011-06-06 | 2011-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR086673A1 true AR086673A1 (es) | 2014-01-15 |
Family
ID=47261858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120101977A AR086673A1 (es) | 2011-06-06 | 2012-06-04 | RESPUESTAS MEJORADAS MEDIADAS POR LES-DC DE CELULAS B QUE SECRETAN IgG E IgA |
Country Status (3)
Country | Link |
---|---|
US (1) | US20120308578A1 (es) |
AR (1) | AR086673A1 (es) |
WO (1) | WO2012170512A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021128027A1 (zh) * | 2019-12-24 | 2021-07-01 | 荣昌生物制药(烟台)股份有限公司 | TACI-Fc融合蛋白及其用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2441848A1 (de) * | 2010-10-12 | 2012-04-18 | Protagen AG | Markersequenzen für systemischer Lupus Erythematodes und deren Verwendung |
-
2012
- 2012-06-04 AR ARP120101977A patent/AR086673A1/es unknown
- 2012-06-06 US US13/489,851 patent/US20120308578A1/en not_active Abandoned
- 2012-06-06 WO PCT/US2012/041079 patent/WO2012170512A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US20120308578A1 (en) | 2012-12-06 |
WO2012170512A1 (en) | 2012-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR084373A1 (es) | Composiciones y metodos para la eliminacion de biopeliculas | |
BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
AR084938A1 (es) | Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes | |
CR20110128A (es) | Metodos, sistemas y productos para predecir la respuesta de las celulas tumorales a un agente terapeutico y tratar a un paciente de acuerdo con la respuesta predicha | |
BR112014017158A8 (pt) | aberturas tratadas | |
CO6390109A2 (es) | Inhibidores de syk de imidazopirazina | |
AR097178A1 (es) | Diagnóstico y terapias anticáncer que comprenden células madre cancerosas | |
AR081874A1 (es) | Metodo para predecir eficacia a un regimen terapeutico en un paciente con adenocarcinomas mediante la expresion de un gen reparador de adn (msh3) | |
Chen et al. | The effect of citalopram on chronic stress-induced depressive-like behavior in rats through GSK3β/β-catenin activation in the medial prefrontal cortex | |
WO2007103373A3 (en) | Compositions and methods for the treatment of immunoinflammatory disorders | |
WO2014205555A8 (en) | Methods and uses for diagnosis and treatment of prostate cancer | |
CL2020002047A1 (es) | Métodos terapéuticos y diagnósticos para enfermedades inflamatorias mediadas por mastocitos. | |
Liu et al. | Metabolic factors-triggered inflammatory response drives antidepressant effects of exercise in CUMS rats | |
WO2009075797A3 (en) | Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma | |
ES2571111T3 (es) | Método de diagnóstico para predicción de la respuesta de un paciente a la quimioviroterapia o radioviroterapia | |
CO6592030A2 (es) | Uso de la tasa de dilatación ventricular en el tratamiento de la enfermedad de alzheimer con inmunoglobulina intravenosa | |
CL2023003003A1 (es) | Tratamiento y diagnóstico de trastornos inflamatorios | |
Mitchell et al. | High salt intake enhances swim stress-induced PVN vasopressin cell activation and active stress coping | |
BRPI0920170A2 (pt) | métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método. | |
Liu et al. | PPM1F in hippocampal dentate gyrus regulates the depression-related behaviors by modulating neuronal excitability | |
EA201290683A1 (ru) | Устройство для ослабления симптомов нейродегенеративных заболеваний | |
Karelina et al. | Social contact influences histological and behavioral outcomes following cerebral ischemia | |
BR112016029996A2 (pt) | utilização cosmética, composição e método cosmético para tratar os odores corporais | |
ES2671248T3 (es) | Métodos para tratar el cáncer que comprenden un guiado por NQO1 | |
AR086673A1 (es) | RESPUESTAS MEJORADAS MEDIADAS POR LES-DC DE CELULAS B QUE SECRETAN IgG E IgA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |